Dyskeratosis Congenita Clinical Trials

Find Dyskeratosis Congenita Clinical Trials Near You

Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

A non-profit, translational, prospective and retrospective study. Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol. Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, we hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF. Therefore, our primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment. In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 28 days
Maximum Age: 65
View:

• Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).

• Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.

Locations
Other Locations
Italy
AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
RECRUITING
Avellino
IRCCS Istituto Giannina Gaslini
RECRUITING
Genova
Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
RECRUITING
Naples
Università degli Studi di Verona Department of Engineering for Innovation Medicine
RECRUITING
Verona
Contact Information
Primary
Carlo Dufour
segrematologia@gaslini.org
+3901056363528
Time Frame
Start Date: 2025-05-29
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 250
Treatments
Fanconi anemia (FA)
Fanconi anemia (FA)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Congenital neutropenia (CN)
Congenital neutropenia (CN)
Primary immune regulatory disorders (PIRD)
Primary immune regulatory disorders (PIRD)
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Sponsors
Leads: Istituto Giannina Gaslini

This content was sourced from clinicaltrials.gov

Similar Clinical Trials